EX-99.2 4 ex992.htm REPORT OF VOTING RESULTS

Exhibit 99.2

ESSA Pharma Inc.

(the “Company”)

Annual General and Special Meeting of Shareholders

(the “Meeting”)

March 28, 2018

REPORT OF VOTING RESULTS

(Pursuant to Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations)

Common Shares represented at the Meeting:	[72,019,196]
Total issued and outstanding Common Shares as at Record Date:	115,521,889
Percentage of issued and outstanding Common Shares represented:	[62.34]%

1. Setting Number of Directors

By ordinary resolution passed by show of hands, the number of directors for the ensuing year was set at eight.

2. Election of Directors

By ordinary resolution passed by ballot vote, the following eight nominees proposed by management were elected as directors of the Company to hold office until the next annual meeting of Shareholders or until their successors are elected or appointed:

Nominee		Votes For				% Votes For				Votes Withheld				% Votes Withheld
David R. Parkinson			68,461,278				99.74	%			179,319				0.26	%
Richard M. Glickman			68,410,188				99.66	%			230,409				0.34	%
Marianne Sadar			68,463,378				99.74	%			177,219				0.26	%
Raymond Andersen			68,461,278				99.74	%			179,319				0.26	%
Gary Sollis			68,583,278				99.92	%			57,319				0.08	%
Franklin M. Berger			68,513,278				99.81	%			127,319				0.19	%
Scott Requadt			68,501,278				99.80	%			139,319				0.20	%
Hugo Beekman			68,501,278				99.80	%			139,319				0.20	%

3. Appointment of Auditor

By ordinary resolution passed by show of hands, Davidson & Company LLP, Chartered Professional Accountants, was appointed auditor of the Company for the ensuing year.

 -2-

4. Stock Option Plan

By ordinary resolution passed by ballot vote, the Company’s stock option plan as set out in Schedule A to the management information circular dated February 23, 2018 and provided to the Company’s shareholders in connection with the Meeting (the “Circular”) was ratified, confirmed and approved:

Votes by Ballot		Votes For				% Votes For				Votes Against				% Votes Against
By all shareholders			61,180,225				89.13	%			7,460,372				10.87	%

5. Stock Option Re-Grant and Repricing, and Extension of Expiry Dates

By ordinary resolution passed by ballot vote, the re-grant, repricing and extension of the expiry dates of certain of the outstanding stock options of the Company granted to certain directors, officers, employees and consultants, as further set out in the Circular was ratified, confirmed and approved:

Votes by Ballot		Votes For				% Votes For				Votes Against				% Votes Against
By all shareholders			61,150,175				89.09	%			7,490,422				10.91	%
By disinterested shareholders			17,151,379				69.60	%			7,490,422				30.40	%

6. Stock Option Grants

By ordinary resolution passed by ballot vote, the grant of an aggregate of 14,523,000 stock options to certain directors, officers, employees and consultants of the Company, as further set out in the Circular was ratified, confirmed and approved:

Votes by Ballot		Votes For				% Votes For				Votes Against				% Votes Against
By all shareholders			61,149,600				89.09	%			7,490,997				10.91	%
By disinterested shareholders			17,150,804				69.60	%			7,490,997				30.40	%

7. Common Share Consolidation

By special resolution passed by ballot vote, the consolidation of the Company’s common shares, as further described in the Circular was approved:

Votes by Ballot		Votes For				% Votes For				Votes Against				% Votes Against
By all shareholders			68,577,197				99.91	%			63,400				0.09	%

 -3-

8. RSU Plan

By ordinary resolution passed by ballot vote, the Company’s restricted share unit plan, as set out in Schedule B to the Circular was ratified, confirmed and approved:

Votes by Ballot		Votes For				% Votes For				Votes Against				% Votes Against
By all shareholders			61,179,700				89.13	%			7,460,897				10.87	%
By disinterested shareholders			17,180,904				69.72	%			7,460,897				30.28	%

No other non-routine business was transacted or voted upon at the Meeting.

Dated: March 28, 2018